drugset / Trial / NCT07664397
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
Phase 1
Not yet recruiting
40 enrolled
University of California, San Francisco
Fortis Therapeutics, Inc. · collabKyntra Bio · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody (\[89Zr\]DFO-YS5) in participants with nerve sheath tumor, bladder cancer, or advanced solid tumor neoplasms.
Timeline
- Start
- 2026-08-01
- Primary completion
- 2029-09-30
- Completion
- 2029-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 89Zr-DFO-YS5 | Diagnostic / imaging agent | 37 mbq | Intravenous |
| Subject | 89Zr-DFO-YS5 | Diagnostic / imaging agent | 111 mbq | Intravenous |